Drug Type Small molecule drug |
Synonyms N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo[d]imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine maleate, I 022, I022 + [1] |
Target |
Mechanism CDK4 inhibitors(Cyclin-dependent kinase 4 inhibitors), CDK6 inhibitors(Cyclin-dependent kinase 6 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
RegulationOrphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Locally advanced breast cancer | Phase 3 | CN | 08 Sep 2023 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | CN | 25 Aug 2023 | |
Hormone receptor positive HER2 negative breast cancer | Phase 3 | CN | 25 Aug 2023 | |
Metastatic breast cancer | Phase 3 | CN | 24 Apr 2023 | |
Advanced Liposarcoma | Phase 2 | CN | 17 Oct 2023 | |
Brain metastases | Phase 2 | CN | 19 Sep 2023 | |
PIK3CA mutation/HR-positive/HER2-negative Breast Cancer | Phase 2 | CN | 19 Sep 2023 | |
Dedifferentiated Liposarcoma | Phase 2 | US | 31 Aug 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 03 Nov 2020 | |
Liposarcoma | Phase 2 | US | - |